Centessa Pharmaceuticals plc (NASDAQ:CNTA) Director Arjun Goyal Buys 417,646 Shares

Centessa Pharmaceuticals plc (NASDAQ:CNTA) Director Arjun Goyal acquired 417,646 shares of the firm’s stock in a transaction that occurred on Friday, May 16th. The shares were bought at an average cost of $12.73 per share, for a total transaction of $5,316,633.58. Following the acquisition, the director now owns 462,585 shares of the company’s stock, valued at $5,888,707.05. This represents a 929.36% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Arjun Goyal also recently made the following trade(s):

• On Thursday, May 15th, Arjun Goyal bought 44,939 shares of Centessa Pharmaceuticals stock. The stock was purchased at an average cost of $12.24 per share, for a total transaction of $550,053.36.

Centessa Pharmaceuticals Stock Down 2.0%

Shares of NASDAQ:CNTA traded down $0.25 during mid-day trading on Monday, reaching $12.26. 459,024 shares of the stock were exchanged, compared to its average volume of 636,688. The stock’s 50 day simple moving average is $13.48 and its 200-day simple moving average is $15.58. The company has a quick ratio of 21.52, a current ratio of 21.52 and a debt-to-equity ratio of 0.15. The company has a market cap of $1.64 billion, a P/E ratio of -8.01 and a beta of 1.53. Centessa Pharmaceuticals plc has a one year low of $7.75 and a one year high of $19.09.

Centessa Pharmaceuticals (NASDAQ:CNTA) last issued its quarterly earnings data on Monday, May 12th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.15. As a group, equities research analysts predict that Centessa Pharmaceuticals plc will post -1.6 EPS for the current year.

Institutional Investors Weigh In On Centessa Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the company. JPMorgan Chase & Co. boosted its stake in Centessa Pharmaceuticals by 1,969.2% during the third quarter. JPMorgan Chase & Co. now owns 135,903 shares of the company’s stock worth $2,173,000 after acquiring an additional 129,335 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its position in Centessa Pharmaceuticals by 39.1% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 18,909 shares of the company’s stock valued at $317,000 after buying an additional 5,316 shares during the period. Wellington Management Group LLP lifted its stake in Centessa Pharmaceuticals by 14.4% in the fourth quarter. Wellington Management Group LLP now owns 115,107 shares of the company’s stock valued at $1,928,000 after purchasing an additional 14,494 shares during the last quarter. Franklin Resources Inc. increased its holdings in Centessa Pharmaceuticals by 0.3% in the 4th quarter. Franklin Resources Inc. now owns 2,308,546 shares of the company’s stock worth $38,668,000 after acquiring an additional 6,000 shares during the last quarter. Finally, Geode Capital Management LLC boosted its holdings in Centessa Pharmaceuticals by 1.2% in the 4th quarter. Geode Capital Management LLC now owns 57,257 shares of the company’s stock worth $959,000 after buying an additional 660 shares during the period. Institutional investors own 82.01% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on CNTA. Morgan Stanley reaffirmed an “overweight” rating and set a $27.00 target price on shares of Centessa Pharmaceuticals in a research report on Friday, March 7th. Chardan Capital began coverage on shares of Centessa Pharmaceuticals in a report on Thursday, May 8th. They issued a “buy” rating and a $30.00 target price on the stock. Guggenheim restated a “buy” rating and set a $28.00 price objective on shares of Centessa Pharmaceuticals in a research note on Wednesday, March 26th. Oppenheimer started coverage on Centessa Pharmaceuticals in a research report on Thursday, May 8th. They set an “outperform” rating and a $6.00 price objective for the company. Finally, Piper Sandler assumed coverage on shares of Centessa Pharmaceuticals in a research note on Monday, March 31st. They issued an “overweight” rating and a $38.00 price target for the company. Nine equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $27.00.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.